A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare any good and bad effects of using a combination of
nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.